Abstracts tagged "SLE"

Abstract Number: 1587 • 2013 ACR/ARHP Annual Meeting
Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S
Hong Kan¹, Saurabh Nagar¹, Jeetvan Patel¹, Anna Oh², Daniel J. Wallace³ and Charles T. Molta⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²University of California San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, joints, and the nervous system. Standard…
Abstract Number: 765 • 2013 ACR/ARHP Annual Meeting
Angiogenic Factor Dysregulation and Risk Of Adverse Pregnancy Outcome In Lupus Pregnancies
Jane E. Salmon¹, Mimi Kim², Marta M. Guerra³, Michael D. Lockshin⁴, Ware D. Branch⁵, Michelle Petri⁶, Carl A. Laskin⁷, Joan T. Merrill⁸, Lisa R. Sammaritano¹, Jill P. Buyon⁹ and S. Ananth Karumanchi¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ¹⁰Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Pregnant women with lupus and APL are at increased risk for adverse outcomes, particularly preeclampsia (PE), yet identification of those destined for complications remains…
Abstract Number: 542 • 2013 ACR/ARHP Annual Meeting
Evidence For Involvement Of C5a Receptor in Human and Murine Lupus Nephritis
Constanze Hess¹, Ditte Tornehave², Peter Helding Kvist², Yvonne Sundström³, Louise Berg³, Iva Gunnarsson⁴, Søren Jacobsen⁵, Claus Haase¹ and Lars Hornum¹, ¹Department of Immunopharmacology, Novo Nordisk A/S, Måløv, Denmark, ²Department of Histology, Novo Nordisk A/S, Måløv, Denmark, ³Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: The complement system plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Apart from the activation of the early components of…
Abstract Number: 2526 • 2013 ACR/ARHP Annual Meeting
An Autoantibody Profile for The Diagnosis Of Systemic Lupus Erythematosus Using the IMMUNARRAY iCHIP™
Chaim Putterman¹, Irene Blanco², Nicole Jordan³, Yves Renaudineau⁴, Vered Daniel Carmi⁵, Rachel Sorek⁵, Ornit Cohen-Gindi⁵, Miriam Lerner⁵, D. Scott Batty⁵, Idan Tamir⁵ and Irun R Cohen^5,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁵ImmunArray, Rehovot, Israel, ⁶Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, recurrent, and potentially fatal multisystem inflammatory disorder mainly affecting women. SLE patients produce antibodies to many different self-antigens,…
Abstract Number: 1591 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Atacicept For Prevention Of Flares In Subjects With Moderate To Severe Systemic Lupus Erythematosus (SLE)
David Wofsy¹, David A. Isenberg², Daiana Licu³, Yong Li⁴, Claudia Pena Rossi³ and Caroline Gordon⁵, ¹Rheumatology/Immunology, University of California San Francisco and NIAID Autoimmunity Centers of Excellence, San Francisco, CA, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Merck Serono S.A., Geneva, Switzerland, ⁴EMD Serono, Rockland, MA, ⁵Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulation factors BLyS and APRIL. Levels of BLyS and APRIL are elevated in patients with SLE.…
Abstract Number: 719 • 2013 ACR/ARHP Annual Meeting
Mammalian Target Of Rapamycin (mTOR) Skews T Cell Lineage Development In Systemic Lupus Erythematosus (SLE)
Hiroshi Kato¹ and Andras Perl², ¹Internal Medicine, Division of Rheumatology, SUNY Upstate Medical University, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: mTOR activity is increased in SLE T cells and its blockade has therapeutic efficacy in SLE. Murine studies showed essential roles of mTORC1 in…
Abstract Number: 543 • 2013 ACR/ARHP Annual Meeting
Inhibiting TWEAK (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects From Neuronal Damage In Murine Neuropsychiatric Lupus
Jing Wen¹, Jessica Doerner², Ariel Stock¹, Jennifer Michaelson³, Linda Burkly³, Maria Gulinello¹ and Chaim Putterman⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³Biogen Idec, Cambridge, MA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by involvement of multiple organs, including the central nervous system. While neuropsychiatric involvement in…
Abstract Number: 1863 • 2013 ACR/ARHP Annual Meeting
SLE Disease Activity In The Mucocutaneus, Vascular and Hematologic Systems Is Associated With An Increase In Plasma Type I Interferon Activity
Elena Gkrouzman¹, Mikhail Olferiev¹, Margaret Robotham¹, Mari Lliguicota¹, Wei-Ti Huang², Elzbieta E. Jacek¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) has been implicated in SLE pathogenesis, and cross-sectional studies have shown that IFN-I pathway activation is associated with multiple disease…
Abstract Number: 1594 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, Depression and Anti N-Methyl-D-Aspartate Receptor Antibodies and Anti- Ribosomal P In Systemic Lupus Erythematosus Patients In Argentina
Graciela Gómez¹, Judith Sarano², Maria de los Angeles Gargiulo¹, María Victoria Collado², Lorena Suarez¹, Daniel Fadel³, Alexandra Panopulos⁴ and Marina Khoury⁵, ¹Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ²Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ³Psychiatric, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁴Neurology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ⁵Research and Teaching, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina
Background/Purpose: Cognitive dysfunction (CD) and depression (D) are common manifestations of neuropsychiatric systemic lupus erythematosus (SLE) and they have been linked to antibodies (abs) like…
Abstract Number: 725 • 2013 ACR/ARHP Annual Meeting
Localization At The Immunological Synapse Of Adaptor Protein Grb2 and PLC Gamma-1 In Non-Stimulated Peripheral Blood T Lymphocytes From Patients With Systemic Lupus Erythematosus Suggests An In Vivo dysregulated Activation State
Nursamaa Abdoel¹, Mireyma Sanchez², Hector Rojas³, Martin Rodriguez⁴ and Ana M. Blasini¹, ¹Sección de Investigación en Inmunoreumatologia, Hospital Universitario de Caracas, Caracas, Venezuela, ²Rheumatology, Hospital Universitario de Caracas, Caracas, Venezuela, ³Instituto de Inmunologia, Escuela de Medicina, Universidad Central de Venezuela, Caracas, Venezuela, ⁴Centro Nacional de Enfermedades Reumáticas, Hospital Universitario de Caracas, Caracas, Venezuela
Background/Purpose: We previously showed an increased metabolic rate of transmembrane adaptor protein LAT in TCR/CD3 stimulated lupus T cells, associated with delocalization of this adaptor…
Abstract Number: 554 • 2013 ACR/ARHP Annual Meeting
Identification Of Stage Specific Genes Associated With Lupus Nephritis and Response To Remission induction In NZB/W Mice
Ramalingam Bethunaickan¹, Celine C. Berthier², Hong-dong Li³, Weijia Zhang⁴, Yuanfang Guan⁵, Matthias Kretzler⁶ and Anne Davidson⁷, ¹Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, ²Nephrology, University of Michigan, Ann Arbor, MI, ³Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ⁴Mount Sinai School of Medicine, New York, NY, ⁵Department of Computational Medicine and Bioinformatics, Department of Medicine, University of Michigan, Ann Arbor, MI, ⁶Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁷Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Our goal was to use transcriptome analysis to elucidate the molecular mechanisms involved in the immunopathogenesis of renal inflammation during the onset, remission and…
Abstract Number: 931 • 2012 ACR/ARHP Annual Meeting
Health Care Utilization Among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation
Candace H. Feldman¹, Linda T. Hiraki², Graciela S. Alarcon³, Jinoos Yazdany⁴, Jun Liu⁵, Michael A. Fischer⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital/ Harvard School of Public Health, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extreme sociodemographic disparities exist among systemic lupus erythematosus (SLE) patients in the development of end-stage renal disease (ESRD) from lupus nephritis. Better resource allocation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].